Affiliated Hospital of Nanjing University of Chinese Medicine (Jiang Su Province Hospital of Chinese Medicine), Nanjing, China; State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
J Ethnopharmacol. 2021 Feb 10;266:113394. doi: 10.1016/j.jep.2020.113394. Epub 2020 Sep 15.
Inflammatory bowel disease (IBD) is a chronic and relapsing inflammatory disease of the gastrointestinal tract, consisting of ulcerative colitis (UC) and Crohn's disease (CD). Gut microbiota and their metabolites may play a role in the pathogen of IBD, especially of the UC. Qingchang Huashi Formula (QHF), a traditional Chinese medicine formula, has shown therapeutic effect on treating UC based on the clinical practice without clear pharmacological mechanism.
The aim of this study was to clearly define the effect of QHF and its components, Baitouweng (PBR) and Baizhi (ADR) on treating UC.
Pharmacodynamic effects of QHF and single herb were evaluated in dextran sulfate sodium (DSS) induced acute or chronic colitis mice. Body weight loss, disease activity index (DAI) and colon length were estimated. Histological changes were observed by H&E staining. The number and abundance of gut microbiota were measured with 16S rRNA sequencing. LC-MS and GC-MS were used to detect the concentration of metabolites (e.g., bile acids (BAs) and short chain fatty acids (SCFAs)). The goblet cell was observed by Alcian blue/periodic acid-Schiff (AB/PAS) straining and the crypt stem cell was estimated by immunohistochemical analyses. The colorectal tissues were used to detect levels of IL-1β, IL-6 and TNF-α by ELISA or qRT-PCR. The expression of NLRP3, Caspase 1 and IL-1β were examined by western blotting.
QHF significantly inhibited colitis, protected mice from the loss of body weight and colon shorten. Comparatively, ADR and PBR showed strong efficacy in inhibiting DSS-induced colitis. We verified that while ADR was responsible for QHF's effect on maintaining gut microbiota homeostasis and metabolism, PBR was more prominent in keeping crypt stem cells proliferation and colonic goblet cells function. Moreover, we demonstrated that the alleviation of colitis by QHF was associated with the restoration of gut microbiota-metabolism homeostasis, protection of intestinal epithelial barrier and regulation of NLRP3/IL-1β pathway.
The finding of the present study suggested that QHF is curative in DSS-induced colitis by restoring gut microbiota-metabolism homeostasis and goblet cells function. An optimized QHF was constituted by ADR and PBR, which showed comparable efficacy on colitis to that of QHF. Our work probed out the active constitutes as well as the relevant pharmacological mechanisms of QHF, shedding light on potential new drug combination for the treatment of IBD.
炎症性肠病(IBD)是一种胃肠道的慢性复发性炎症性疾病,包括溃疡性结肠炎(UC)和克罗恩病(CD)。肠道微生物群及其代谢物可能在 IBD 的发病机制中发挥作用,特别是在 UC 中。 Qingchang Huashi 配方(QHF)是一种中药配方,基于临床实践,已显示出治疗 UC 的疗效,但其药理机制尚不清楚。
本研究的目的是明确 QHF 及其成分白芍(PBR)和白芷(ADR)对 UC 的治疗作用。
采用葡聚糖硫酸钠(DSS)诱导的急性或慢性结肠炎小鼠评价 QHF 和单味药的药效学作用。通过疾病活动指数(DAI)和结肠长度来评估体重减轻情况。通过 H&E 染色观察组织学变化。采用 16S rRNA 测序检测肠道微生物群的数量和丰度。采用 LC-MS 和 GC-MS 检测代谢物(如胆汁酸(BAs)和短链脂肪酸(SCFAs))的浓度。通过阿尔辛蓝/过碘酸希夫(AB/PAS)染色观察杯状细胞,通过免疫组织化学分析评估隐窝干细胞。通过 ELISA 或 qRT-PCR 检测结肠组织中 IL-1β、IL-6 和 TNF-α的水平。采用 Western blot 检测 NLRP3、Caspase 1 和 IL-1β的表达。
QHF 能显著抑制结肠炎,防止小鼠体重减轻和结肠缩短。相比之下,ADR 和 PBR 对抑制 DSS 诱导的结肠炎具有较强的疗效。我们验证了 ADR 负责 QHF 维持肠道微生物群代谢平衡和代谢的作用,而 PBR 则更突出地保持隐窝干细胞增殖和结肠杯状细胞功能。此外,我们还证明,QHF 通过恢复肠道微生物群-代谢平衡、保护肠道上皮屏障和调节 NLRP3/IL-1β通路来缓解结肠炎。
本研究表明,QHF 通过恢复肠道微生物群-代谢平衡和杯状细胞功能对 DSS 诱导的结肠炎有治疗作用。ADR 和 PBR 组成的优化 QHF 在治疗结肠炎方面与 QHF 疗效相当。我们的工作探究了 QHF 的有效成分以及相关的药理机制,为 IBD 的治疗提供了新的药物组合的潜力。